Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
Acceptance reinforces Fresenius Kabi’s strategy to expand its autoimmune biosimilars portfolio and broaden patient access to biologic medicines
July 31, 2026